Protox Therapeutics Inc. (“Protox”, TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced that it has entered into a US $15 million loan agreement ...

Canada's Protox Therapeutics has landed a $75 million development and commercialization agreement with Japan-based Kissei Pharmaceutical. The $75 million deal covers PRX302, Protox's PSA-activated pro ...

VANCOUVER, Oct. 8 /CNW/ - Protox Therapeutics Inc. (TSX: PRX - News), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its Phase 1 study of ...

Last month, the British Association of Plastic Surgeons revealed that cosmetic surgery is down 40 per cent. But it could be that people are turning towards non-surgical options, such as Botox - it ...

Shareholders of Vancouver-based Protox Therapeutics Inc. (TSX:PRX) have approved multi-stage financing that could see a global private equity firm become the company’s majority shareholder. Under the ...

PRX302 is currently in North American Phase II evaluation as PSA-activated pore-punching prodrug. Kissei Pharamaceutical is paying Protox Therapeutics $3 million up front for exclusive Japanese rights ...

It's not easy keeping a poker face. I mean there are so many times when I meet people and it would be beneficial to keep a straight face, but sometimes it's just so hard! When a patient tells me they ...

VANCOUVER , Jan. 11 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded ...

VANCOUVER – Protox Therapeutics Inc. (TSX:PRX), a developer of drugs to treat urological diseases, said Monday it has entered into a US $15 million loan agreement with a U.S. lender to help the ...

VANCOUVER, June 2 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo ...